Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Condition(s)
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
Molecular Target(s)
EGFR, MET
Drug Classification(s)
Immunotherapy
Agents(s)
NSCLC, UC, Melanoma, ccRCC, and HNSCC
Phase(s)
I/II
Mechanism of Action
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
Purpose
n/a
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000